Log In

Business Overview

The convergence of physical structural engineering and biological computation.

01

Living Systems Intelligence (LSI)

The LSI division focuses on the intelligent design of biological interfaces. By leveraging proprietary bio-synthetic frameworks, LSI ensures that therapeutic interactions are precisely managed at the cellular level, drastically reducing systemic toxicity and increasing efficacy.

  • Core Product: LSI-Matrix™ (injectable hydrogel)
  • Market: Oncology, Orthopedics
  • Status: Commercial Stage ($450M ARR)
02

CytosAI (Computational Biology)

CytosAI utilizes a proprietary generative transformer model trained on 500PB of proprietary proteomic data. It predicts protein folding and interaction specifically within the LSI-Matrix environment, reducing drug discovery timelines by approximately 70%.

  • Core Product: Cytos-V (In-silico trial platform)
  • Market: Pharma Partnerships, Internal R&D
  • Status: High-Growth SaaS + Milestone Payments

Strategic Flywheel

Data generated from LSI's physical applications feeds directly into CytosAI's training models. Conversely, CytosAI optimizes the composition of LSI matrices for specific patient profiles. This closed-loop data advantage creates a widening competitive moat.